Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.53 |
| ▸ | PI4KA | P42356 | 3/20 | 0.53 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.53 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | HCAR1 | Q9BXC0 | 5/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2951838 | 0.98 | ADORA2A (0.51) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| Hydrochloric Acid SCHEMBL6821629 | 0.97 | ADORA2A (0.50) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL1375991 | 0.95 | ADORA2A (0.51) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL19553770 | 0.91 | ADORA2A (0.49) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20547471 | 0.79 | CYP2C19 (0.54) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4373722 | 0.78 | SRC (0.40) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| Hydrochloric Acid SCHEMBL7659251 | 0.77 | ABL1 (0.39) | ADORA2AHCAR1JAK2PRKCAKDR | |
| Hydrochloric Acid SCHEMBL7843046 | 0.77 | ABL1 (0.39) | ADORA2AHCAR1JAK2PRKCAKDR | |
| Hydrochloric Acid SCHEMBL7659259 | 0.77 | ABL1 (0.39) | ADORA2AHCAR1JAK2PRKCAKDR | |
| Hydrochloric Acid SCHEMBL7659256 | 0.77 | ABL1 (0.39) | ADORA2AHCAR1JAK2PRKCAKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119384510-A | Method for converting human somatic cells into proliferating neural stem cells | 高丽大学校产学协力团 | 2025-01-28 | — | — | CN | disclosed |
| EP-3452477-B1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B C I PHARMA (BE) | 2023-09-13 | — | — | EP | disclosed |
| CN-116368220-A | Closed manufacturing process for large-scale production of pluripotent stem cell-derived cells | 诺卡迪亚有限公司 | 2023-06-30 | — | — | CN | disclosed |
| WO-2022080473-A1 | NERVE CELL ACTIVATOR | 三沢幸子 | 2022-04-21 | — | — | WO | disclosed |
| CN-109311882-B | Adenine derivatives as protein kinase inhibitors | BCI制药公司 | 2022-02-11 | — | — | CN | disclosed |
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | B.C.I. PHARMA (BE) | 2022-02-01 | — | — | US | disclosed |
| CN-112055738-B | Freezing point depression cycle control system, method and device | 再合科技有限公司 | 2021-07-13 | — | — | CN | disclosed |
| CN-112055738-A | Freezing point depression cycle control system, method and device | 再合科技有限公司 | 2020-12-08 | — | — | CN | disclosed |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2019-05-02 | — | — | US | disclosed |
| EP-3452477-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. Pharma (BE) | 2019-03-13 | — | — | EP | disclosed |
| CN-109311882-A | adenine derivatives as protein kinase inhibitors | BCI制药公司 | 2019-02-05 | — | — | CN | disclosed |
| WO-2017191297-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | BCI PHARMA (FR) | 2017-11-09 | — | — | WO | disclosed |
| CN-1013448-B | N6Process for producing-substituted deoxyriboadenosine analogues | WARNER LAMBERT CO (US) | 1991-08-07 | — | — | CN | disclosed |
| EP-0181129-B1 | N6-SUBSTITUTED DEOXYRIBOSE ANALOGS OF ADENOSINES | WARNER-LAMBERT COMPANY (US) | 1989-03-08 | — | — | EP | disclosed |
| CN-85108658-A | N 6The manufacture method that replaces ribodesose adenyhomotype thing | — | 1986-07-16 | — | — | CN | disclosed |
| EP-0181129-A2 | N6-substituted deoxyribose analogs of adenosines | WARNER-LAMBERT COMPANY (US) | 1986-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | ADK, TNNI3K, TNK2 | ADORA2A 195/4885PI4KA 321/4885PI4K2B 659/4885 |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ADK, TNNI3K, TNK2 | ADORA2A 195/4885PI4KA 321/4885PI4K2B 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.